Nomura Holdings
MREO

Nomura Holdings’s Mereo BioPharma MREO Stock Holding History

Nomura Holdings’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-103,800
Closed -$214K – 2063
2025
Q3 		$214K Sell
103,800
-21,200
-17% -$39.1K ﹤0.01% 1772
2025
Q2 		$339K Buy
+125,000
New +$302K ﹤0.01% 1216

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Nomura Holdings's MREO Position: Q4 2025 in Review

Nomura Holdings sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 103,800 shares — an estimated $214K sold.

Nomura Holdings first reported a position in MREO in Q2 2025 and held it in 2 quarters. The position peaked at $339K in Q2 2025. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Nomura Holdings reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Nomura Holdings sold 103,800 Mereo BioPharma shares in Q4 2025, an estimated $214K.
  • Nomura Holdings first reported a position in Mereo BioPharma in Q2 2025 and held it in 2 quarters.
  • Nomura Holdings's Mereo BioPharma position peaked at $339K in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.